Conference
The Brain Mosaic: Cellular heterogeneity in the CNS
October 10-11
Leuven Belgium
Visit us
Conference Information
Join us in Belgium for the Brain Mosaic: Cellular heterogeneity in the CNS conference!
Meet us on-site and discover our universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research.
Our solutions allow you to minimize validation challenges and move fast from biomarker discovery to translational research.
Want to know more about our spatial biology solutions? Send us a message and secure a meeting with the team.
Brain Mosaic: Cellular heterogeneity in the CNS
Poster session
| Glioblastoma (GBM) is the most aggressive primary neuroepithelial tumor diagnosed in about 14,000 people in the United States. Various biomarkers are used for immunohistochemical (IHC) diagnosis of GBM, including Isocitrate dehydrogenase 1 (IDH1), Epidermal Growth Factor Receptor (EGFR), Insulin-Like Growth Factor 1 Receptor (IGFR), and cell proliferating marker Ki-67. Typically, IHC is done by using a single-biomarker detection technique, which is not suitable for the simultaneous spatial analysis of multiple biomarkers. In a previous study, we developed a manual protocol for multiplex IHC for the colocalization of the above targets. Here, we employ the fully automated COMET™ platform to perform spatial biology analysis of the distribution and co-localization of biomarkers across GBM sections. A sequential immunofluorescence (seqIF™) protocol was performed on COMET™ (PMID: 37813886) for the spatial detection of EGFR, IGF1R, and Ki-67. As in our previous manual IHC staining protocol, we observed a high frequency of EGFR and IDH1 co-localization, whereas IGF1R labeling was confined to a smaller number of cells. Immunoreactivity for Ki-67 was the lowest and was detected in about 5% of cells. A large number of EGFR-positive cancer cells were also immunoreactive for IDH1 and IGF1R. We observed that the entire population of Ki-67-labeled cells was also immunoreactive for EGFR and IDH1, and only half of Ki-67-positive cells were immunoreactive for IGF1R. Using COMET™ automated workflow, we could reduce assay time while keeping a high resolution for rapid analysis of the spatial distribution of multiple GBM biomarkers and their co-localization at the single-cell level. |
Speaker
Mila Basic, Ph.D.
Technical Sales Specialist
Lunaphore Technologies